Heart Disease News and Research

Latest Heart Disease News and Research

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

15 Mar 2010

Medtronic commences clinical evaluation of CoreValve transcatheter aortic valve system

Moving to expand the evidence base for the future of structural heart disease therapy, Medtronic, Inc., today announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system, a minimally-invasive alternative to open-heart surgery for aortic valve replacement.

15 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

New hydrosurgery system may help manage excessive bleeding during surgery

Carnegie Mellon University's Matt Oberdier is developing a new hydrosurgery system to help physicians better manage excessive bleeding during surgery.

15 Mar 2010

FDA warns patients and physicians about the efficacy of Plavix treatment

The U.S. Food and Drug Administration today added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.

15 Mar 2010

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

15 Mar 2010

Medicare to cover OVA1 test

Vermillion, Inc. today announced that Medicare will cover OVA1™, a test to help assess the likelihood that an ovarian mass is benign or malignant. Highmark Medicare Services is the CMS contractor that will process Medicare claims for OVA1. Yesterday Highmark announced its decision to cover this new service.

12 Mar 2010

Royal Philips Electronics, ACC to present Hybrid OR Suite designed for cardiac procedures at ACC 2010

Royal Philips Electronics, in partnership with the American College of Cardiology, spotlight the growing need for minimally-invasive interventions to address a spectrum of cardiac conditions, such as structural and degenerative heart issues. The need to reduce invasive surgical interventions and complication rates is driving innovations in minimally invasive approaches.

From Philips Healthcare 12 Mar 2010

Telemonitoring may reduce mortality of heart failure patients by 20%

Telemonitoring may reduce the mortality of patients with heart failure by 20%. Silke Schmidt et al. present their study results in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[8]131-8).

12 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

Experts: Americans get too many tests, too much treatment

"Too much cancer screening, too many heart tests, too many cesarean sections. A spate of recent reports suggest that too many Americans -- maybe even President Barack Obama -- are being overtreated." Defensive medicine and a culture focusing on medical technology have lead to overtesting but "now new evidence and guidelines are recommending a step back and more thorough doctor-patient conversations about risks and benefits."

12 Mar 2010

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

St. Jude Medical, Inc. today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

12 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics is reporting its financial results for the year ended December 31, 2009.

From Evident Corporation - Life Sciences 12 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

LUMEDX announces latest addition to its CardioPACS imaging solution

LUMEDX, a leading provider of fully integrated cardiovascular information systems, announces the latest addition to its CardioPACS imaging solution: an interface to QLAB, proprietary ultrasound software from Philips. Through Philips’ QLAB advanced 2D and 3D ultrasound quantification tools within the LUMEDX CardioPACS application, facilities using Philips ultrasound systems can now enjoy greater efficiencies and enhanced accuracy of diagnosis.

12 Mar 2010

New micromanipulator for precise operations involving cochlear and middle ear implants

A team of engineers from the CEIT-IK4 technological centre and doctors from the University Hospital of Navarra have designed a new tool for operating on the inner ear with maximum precision, reducing the possibility of damage to the auditory function during the surgery. This is the first micromanipulator specifically for operations involving cochlear and middle ear implants, of which about a hundred are carried out in this hospital annually. Taking part in developing the new tool were four engineers from CEIT and five ear, nose and throat specialists from the University Hospital of Navarra.

12 Mar 2010

Study shows experimental thyroid drug reduces cholesterol

An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

12 Mar 2010

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical.

From Baxter International Inc. 12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Heart Disease News and Research

Latest Heart Disease News and Research

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Medtronic commences clinical evaluation of CoreValve transcatheter aortic valve system

New study finds green tea extract may prevent Alzheimer's disease and dementia

New hydrosurgery system may help manage excessive bleeding during surgery

FDA warns patients and physicians about the efficacy of Plavix treatment

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Medicare to cover OVA1 test

Royal Philips Electronics, ACC to present Hybrid OR Suite designed for cardiac procedures at ACC 2010

Telemonitoring may reduce mortality of heart failure patients by 20%

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Experts: Americans get too many tests, too much treatment

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Cytori Therapeutics reports total revenues of $14.7M for 2009

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

LUMEDX announces latest addition to its CardioPACS imaging solution

New micromanipulator for precise operations involving cochlear and middle ear implants

Study shows experimental thyroid drug reduces cholesterol

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Heart Disease News and Research

Latest Heart Disease News and Research

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in